Kite Pharma, Inc. (KITE) shares saw a recent bid of $76.64 and 1.14M shares have exchanged hands in the recent trading session, yielding a 5.89% gain over the past week. The stock price increased 4.12% or $-3.03 versus $73.61 at the end of the prior session. This change led market cap to move at $4.29B, putting the price -13.48% below the 52-week high and 92.47% above the 52-week low. The company’s stock has a normal trading capacity of 1.44M shares while the relative volume is 0.79.
To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $84.50 while $101.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $16.5 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $54.00, which would be decrease of about -30% of its current value. The mean target of $87.50 should be compared with the price when the stock was languishing around $39.82 a share. And it remains to be seen which target price KITE can achieve without sacrificing much as the company is holding a 33.47% gain for the past twelve months.
By historical standards, Kite Pharma, Inc. remains a cheap stock. For now, Kite Pharma, Inc. is the toast of Wall Street as its ABR stands at 2.30 with 4 out of 14 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Kite Pharma, Inc. has a 18.39% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Kite Pharma, Inc. has far performed well this year, with the share price up 70.92% since January. Over the past 2 quarters, the stock is up 50.99%, compared with a gain of nearly 3.05% for 3 months and about -6.29% for the past 30 days.
Last time, the company failed Wall Street by reporting EPS of $-1.74, smashing the consensus of $-1.71 per share. Revenue for the quarter also killed consensus, coming in at $9.84M, compared to the consensus of 12.31M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-1.90. The company is expected to report EPS as high as $-1.53 and as low as $-2.07 per share. Similarly, full-year EPS forecasts have ranged between $-8.80 and $-6.63. The mean EPS estimate is $-8.17. On the other side, sales forecasts for the current quarter are $9.81M. The stock is expected to report revenue as high as $12.5M and as low as $5M per share. Similarly, full-year sales forecasts have ranged between $26.1M and $49.8M. The mean revenue estimate is $41.64M.
Over the last 5 years, Analysts are expecting EPS growth rates to be at -134.30% this quarter and EPS estimate for next year reflect 21.30% growth rate.
Sell-side analysts also have something to say about this company. FBR & Co. analysts stated on 09/05/2017 that they maintained their Outperform rating. Wedbush had a markedly different take on 09/05/2017, proposing that Kite Pharma, Inc. is now considered Underperform versus prior Neutral rating. Raymond James had a markedly different take on 08/05/2017, proposing that Kite Pharma, Inc. is now considered Mkt Perform versus prior Outperform rating. Standpoint Research had a markedly different take on 13/03/2017, proposing that Kite Pharma, Inc. is now considered Hold versus prior Buy rating.